Literature DB >> 11895554

Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1.

Tomohiko Akahoshi1, Makoto Hashizume, Kazuo Tanoue, Rinshyun Shimabukuro, Norikazu Gotoh, Mormasa Tomikawa, Keizo Sugimachi.   

Abstract

BACKGROUND: The effect of the spleen on the cirrhotic liver is unknown. Transforming growth factor-beta 1 (TGF-beta 1), which plays a crucial role in the matrix production during liver fibrosis, is an inhibitory factor regarding the regeneration of hepatocytes. In this study, we investigated the TGF-beta 1 production in the spleen of cirrhotic rats and the effects of a splenectomy on the healing process from liver fibrosis.
METHODS: Thirty-six Wistar male rats were used. Thioacetamide (TAA) was administered intraperitoneally for 24 weeks. The rats underwent either a sham operation (TAA + Sham) or a splenectomy (TAA + SPL). The improvements in liver fibrosis and liver regeneration were investigated 10, 30 and 60 days after the operations in each group. The effect of a splenectomy on the plasma concentration of TGF-beta 1 in the portal vein was investigated by ELISA. The TGF-beta 1 expressions in the spleen were measured using immunohistochemical staining and the degree of such expression was measured using RT-PCR. The activity of TGF-beta 1 in the portal vein of TAA + Sham and TAA + SPL was assessed by the inhibiting effect of rat parenchymal hepatocyte proliferation in primary culture.
RESULTS: Liver regeneration (PCNA-labeling index) in the TAA + SPL rats was stimulated more at 10 and 30 days after the operation (P < 0.05) than in the TAA + Sham rats, and the improvement of liver fibrosis (fibrosis rate) in the TAA + SPL rats was higher at 60 days (P < 0.05) than in the TAA + Sham rats. The plasma concentration of TGF-beta1 of the portal vein in TAA + SPL rats was significantly lower than in the TAA + Sham rats for each period. Immunohistochemically, TGF-beta1-positive stained cells were recognized in the spleen macrophages in the red pulp of cirrhotic rats. The plasma of the TAA + Sham rats at 10 and 30 days after the operation was significantly stronger than that of the TAA + SPL rats in inhibiting the proliferation of rat hepatocytes of primary culture. Inhibitory effects were then dose-dependently neutralized by monoclonal TGF-beta 1 antibody.
CONCLUSION: Spleen-derived TGF-beta 1 may thus play an inhibitory role in the healing of liver cirrhosis by inhibiting the regeneration of the damaged liver.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895554     DOI: 10.1046/j.1440-1746.2002.02667.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  31 in total

1.  Migration of splenic lymphocytes promotes liver fibrosis through modification of T helper cytokine balance in mice.

Authors:  Kazutaka Tanabe; Kojiro Taura; Yukinori Koyama; Gen Yamamoto; Takahiro Nishio; Yukihiro Okuda; Kojiro Nakamura; Kan Toriguchi; Kenji Takemoto; Kenya Yamanaka; Keiko Iwaisako; Satoru Seo; Masataka Asagiri; Etsuro Hatano; Shinji Uemoto
Journal:  J Gastroenterol       Date:  2015-02-28       Impact factor: 7.527

2.  Splenectomy enhances the anti-fibrotic effect of bone marrow cell infusion and improves liver function in cirrhotic mice and patients.

Authors:  Takuya Iwamoto; Shuji Terai; Yuko Mizunaga; Naoki Yamamoto; Kaoru Omori; Koichi Uchida; Takahiro Yamasaki; Yasuhiko Fujii; Hiroshi Nishina; Isao Sakaida
Journal:  J Gastroenterol       Date:  2011-11-09       Impact factor: 7.527

3.  Spleen-derived lipocalin-2 in the portal vein regulates Kupffer cells activation and attenuates the development of liver fibrosis in mice.

Authors:  Tomonori Aoyama; Kyoko Kuwahara-Arai; Akira Uchiyama; Kazuyoshi Kon; Hironao Okubo; Shunhei Yamashina; Kenichi Ikejima; Shigehiro Kokubu; Akihisa Miyazaki; Sumio Watanabe
Journal:  Lab Invest       Date:  2017-05-15       Impact factor: 5.662

4.  Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis.

Authors:  Xing Lv; Fan Yang; Xin Guo; Tao Yang; Ti Zhou; Xiaoping Dong; Yong Long; Dan Xiao; Yong Chen
Journal:  Tumour Biol       Date:  2016-01-11

5.  Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.

Authors:  Vyacheslav U Buko; Oxana Y Lukivskaya; Elena E Naruta; Elena B Belonovskaya; Horst-Dietmar Tauschel
Journal:  J Clin Exp Hepatol       Date:  2014-02-21

6.  Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study.

Authors:  Xiao-Yun Zhang; Chuan Li; Tian-Fu Wen; Lu-Nan Yan; Bo Li; Jia-Yin Yang; Wen-Tao Wang; Li Jiang
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

7.  Comparison of liver regeneration after a splenectomy and splenic artery ligation in a dimethylnitrosamine-induced cirrhotic rat model.

Authors:  Akio Morinaga; Toshiro Ogata; Masayosi Kage; Hisafumi Kinoshita; Sigeaki Aoyagi
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

8.  Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension.

Authors:  Azusa Kitao; Yasunori Sato; Seiko Sawada-Kitamura; Kenichi Harada; Motoko Sasaki; Hiroyasu Morikawa; Susumu Shiomi; Masao Honda; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

9.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

10.  Niche-Mediated Integrin Signaling Supports Steady-State Hematopoiesis in the Spleen.

Authors:  Shubham Haribhau Mehatre; Irene Mariam Roy; Atreyi Biswas; Devila Prit; Sarah Schouteden; Joerg Huelsken; Catherine M Verfaillie; Satish Khurana
Journal:  J Immunol       Date:  2021-02-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.